

Cite this: *Chem. Commun.*, 2020, **56**, 11981

Received 9th July 2020,
Accepted 30th August 2020

DOI: 10.1039/d0cc04750c

rsc.li/chemcomm

There is currently a lack of efficient reagents to transfet cells with large plasmid DNA, which would be enabling tools for gene editing using CRISPR/Cas9 technology. Herein, we report the discovery of peptide dendrimer Z22 as a non-viral vector for transfeting large CRISPR/Cas9 pDNA into 3D-tumor spheroids with exceptionally high efficiency, low cytotoxicity and low immunogenicity.

Gene editing using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) has revolutionized biology and provides fascinating opportunities as a therapeutic tool.^{1–3} One of the key challenges in this technology is to deliver CRISPR/Cas9 plasmid DNA (pDNA) into the target cells because the plasmid is relatively large, limiting the use of viral vectors such as adeno-associated virus (AAV) due to their low encapsulation capacity.^{4,5} Non-viral vectors, typically consisting of cationic lipids or polycationic polymers, should be better suited to deliver CRISPR/Cas9 pDNA because they can accept larger payloads, while having generally a better safety profile in terms of cytotoxicity and immunogenicity and being easier to manufacture than viral vectors.⁶ Unfortunately non-viral vectors often have limited tissue penetration,^{7,8} and perform only very poorly with pDNA, for example requiring the use of detached cells by transfection or electroporation when editing organoids.^{9,10} Here we focused on transfeting 3D-tumor spheroids, which present several unique features found in tissues, such as chemical gradients of oxygen and nutrients at diameters starting from 200 μ m and the production of an extracellular matrix as a structural and biochemical support.¹¹ Transfeting such 3D-tumor spheroids is very difficult and has so far only been achieved with very low efficiency using transfection reagents based on poly(β -amino ester) and glycogen nanoparticles.^{12,13}

We aimed for a peptide dendrimer¹⁴ as a non-viral vector because dendrimers^{15–17} and peptide-type oligomers^{18–20} are

Transfeting tissue models with CRISPR/Cas9 plasmid DNA using peptide dendrimers†

Susanna J. Zamolo, Tamis Darbre * and Jean-Louis Reymond *




Fig. 1 Synthesis and structure of peptide dendrimer Z22. Conditions: (a) (i) Fmoc-amino acid (5 equiv./coupling site), oxyma (5 equiv.), DIC (5 equiv.) in DMF, 1–5 min, 75–90 °C; (ii) piperidine/DMF (1 : 4, v/v), 2 min, 75–90 °C; (iii) P(PPH₃)₄ (0.25 equiv./alloc group), (CH₃)₂NH-BH₃ (25 equiv./alloc group), 2 × 60 min, 25 °C; (iv) stearic acid (5 equiv.), DIC (5 equiv.), oxyma (5 equiv.) in NMP, 60 min-overnight; (v) TFA (94%), i-Pr₂SiH (2.5%), DODT (2.5%), H₂O (1%), 5 h, 25 °C. (b) Reversed phase C18 preparative HPLC, gradient 0–70% CH₃CN/H₂O/0.1% TFA over 45 min.

Department of Chemistry and Biochemistry, University of Bern, Freiestrasse 3, 3012 Bern, Switzerland. E-mail: jean-louis.reymond@dcb.unibe.ch

† Electronic supplementary information (ESI) available. See DOI: [10.1039/d0cc04750c](https://doi.org/10.1039/d0cc04750c)



both known to be favorable for this task. Specifically, we set out to obtain a peptide dendrimer for pDNA transfection by combining a hydrophobic core similar to the core of peptide dendrimers **DMH13** and **DMH18**, which we recently reported as single component transfection reagents for siRNA,^{21,22} with the branches of peptide dendrimer **G123KL** acting as a co-transfection reagent with lipofectin for DNA,²³ siRNA^{24,25} and oligonucleotides.²⁶

We synthesized peptide dendrimers by standard Fmoc solid-phase peptide synthesis (SPPS, Fig. 1 and Table 1). We tested pDNA transfection on HEK293 and HeLa cells using a commercial 9 Kbp “all-in-one” pDNA vector expressing CRISPR/Cas9 and GFP linked by a self-cleavable 2A peptide,²⁷ together with a gRNA sequence targeting β -glucuronidase. In this assay **DMH13**, **DMH18** and **G123KL**/lipofectin were all less active than the reference reagent lipofectamine L2000.

An initial series of dendrimers showed a significant transfection level when using one (**Z1**) or two (**Z2**) side-chain stearoylated (C_{18}) lysines as the dendrimer core, while dendrimers with other lipidations or buffering histidines at the core or in the branches were less active or totally inactive (**Z3–Z11**, Table S1, ESI[†]). Transfection improved slightly by adding a core cysteine residue to **Z1** (\rightarrow **Z12**) or **Z2** (\rightarrow **Z13**), but not when adding a serine (\rightarrow **Z14**) or alanine (\rightarrow **Z15**). Furthermore, while inserting a second cysteine reduced transfection (**Z12** \rightarrow **Z16**), the disulfide bridged dimer **Z17** was slightly more active than **Z12**. Following up on both of these compounds, we obtained a further increase in pDNA transfection efficiency by using α -enantiomeric residues in the third generation dipeptide branches (\rightarrow **Z18**, **Z19**). The increase was particularly large with the full α -enantiomers (\rightarrow **Z20**, **Z21**), which both surpassed

Table 1 Synthesis and pDNA transfection activity of peptide dendrimers

No.	Sequence ^a	Yield ^b mg (%)	MS ^c calc./obs.	% GFP pos. HEK cells ^d	% GFP pos. HeLa cells ^d	% free DNA ^e	% cytotox. HEK cells ^g	% viability HEK cells ^g
L2000	—	—	—	44.5 \pm 6.2	34.2 \pm 10.0	21.7 \pm 1.9	6.6 \pm 8.5	85 \pm 6.4
DMH13	(kl) ₈ (kkl) ₄ (kll) ₂ k(C ₁₆)k(C ₁₆)	128.4 (7)	4992.83/4992.84	28.9 \pm 2.1	2.6 \pm 2.4	13.1 \pm 2.2	0.9 \pm 1.3	96 \pm 5.6
DMH18	(kl) ₈ (kkl) ₄ (kll) ₂ kllll	73.6 (11)	4712.51/4712.52	5.8 \pm 2.5	0.6 \pm 0.3	11.7 \pm 2.3	1.8 \pm 1.1	91 \pm 13
G123KL	(KL) ₈ (KKL) ₄ (KKL) ₂ KGSC ^f	7.23 (9)	4539.0/4540.1	8.0 \pm 2.7	4.0 \pm 1.9	34.8 \pm 6.2	2.3 \pm 1.3	52 \pm 8.6
(1) Optimization of the lipid core:								
Z1	(KL) ₈ (KKL) ₄ (KKL) ₂ KK(C ₁₈)	8.8 (2)	4684.55/4684.57	10.7 \pm 3.2	2.4 \pm 2.2	7.3 \pm 1.7	11.3 \pm 1.1	64 \pm 7.0
Z2	(KL) ₈ (KKL) ₄ (KKL) ₂ KK(C ₁₈)K(C ₁₈)	1.1 (1)	5078.91/5078.92	11.7 \pm 3.6	2.0 \pm 1.4	12.4 \pm 2.8	2.3 \pm 0.6	79 \pm 11
(2) Cysteine insertion								
Z12	(KL) ₈ (KKL) ₄ (KKL) ₂ KK(C ₁₈)C	1.5 (2)	4787.56/4787.57	12.0 \pm 3.0	3.8 \pm 2.5	5.4 \pm 1.5	3.8 \pm 0.7	80 \pm 5.3
Z13	(KL) ₈ (KKL) ₄ (KKL) ₂ KK(C ₁₈)K(C ₁₈)C	4.4 (3)	5181.92/5181.93	12.8 \pm 2.1	1.4 \pm 0.5	7.5 \pm 6.9	2.9 \pm 0.9	60 \pm 10
Z14	(KL) ₈ (KKL) ₄ (KKL) ₂ KK(C ₁₈)S	3.6 (3)	4771.59/4771.60	7.4 \pm 1.6	2.1 \pm 1.9	6.7 \pm 3.5	4.9 \pm 0.9	62 \pm 6.5
Z15	(KL) ₈ (KKL) ₄ (KKL) ₂ KK(C ₁₈)A	8.3 (5)	4755.59/4755.60	10.1 \pm 2.4	1.0 \pm 0.9	5.8 \pm 5.0	3.0 \pm 0.2	71 \pm 6.9
Z16	(KL) ₈ (KKL) ₄ (KKL) ₂ KK(C ₁₈)CC	5.1 (3)	4890.57/4890.58	9.5 \pm 2.6	1.7 \pm 1.0	7.1 \pm 1.3	1.1 \pm 0.7	62 \pm 11
Z17	((KL) ₈ (KKL) ₄ (KKL) ₂ KK(C ₁₈)C) ₂	1 (1)	9573.11/9573.10	15.0 \pm 5.7	3.5 \pm 1.0	11.7 \pm 8.6	3.7 \pm 0.8	106 \pm 12
(3) Stereochemistry and cationic residues								
Z18	(kl) ₈ (KKL) ₄ (KKL) ₂ KK(C ₁₈)C	5.3 (5)	4787.56/4787.57	16.7 \pm 3.9	2.9 \pm 1.1	4.2 \pm 2.7	1.7 \pm 0.7	70 \pm 7.0
Z19	((kl) ₈ (KKL) ₄ (KKL) ₂ KK(C ₁₈)C) ₂	1.5 (5)	9573.11/9574.13	15.4 \pm 5.6	4.2 \pm 2.0	13.7 \pm 2.1	3.3 \pm 0.7	62 \pm 5.6
Z20	(kl) ₈ (kkl) ₄ (kkl) ₂ kk(C ₁₈)c	3.1 (5)	4787.56/4787.57	51.6 \pm 12.5	34.2 \pm 13.1	10.6 \pm 2.1	3.7 \pm 1.4	85 \pm 8.7
Z21	((kl) ₈ (kkl) ₄ (kkl) ₂ kk(C ₁₈)c) ₂	3.2 (5)	9573.11/9573.13	55.0 \pm 10.6	37.2 \pm 12.6	10.1 \pm 4.0	5.0 \pm 2.8	63 \pm 9.6
Z22	(rl) ₈ (krl) ₄ (krl) ₂ kk(C ₁₈)c	7.8 (4)	5179.65/5179.66	62.5 \pm 9.5	47.3 \pm 9.3	6.5 \pm 1.8	4.7 \pm 2.5	83 \pm 8.5

^a One-letter code amino acids are used, *K* is the branching lysine residue, C-termini are carboxamide CONH₂, and all N-termini are free. Alkyl chains in the structure are represented by “C” followed by their number of carbon atoms. ^b Isolated yields as trifluoroacetate salt after preparative HPLC purification. ^c ESI-MS, see also the ESI. ^d Transfection efficiency in HEK and HeLa cells measured as the percentage of GFP positive cells after 48 h of transfection. Experiments were carried out in triplicate in three independent experiments (N/P 5, 175 pmol of peptide dendrimers in 100 μ L Optimem per well, 1.7 μ M, 250 ng pDNA). ^e Fluorescence from intercalation in the pDNA/peptide dendrimer complex at N/P 5 (200 μ L, final concentration of 0.085 nM pDNA and 0.35 μ M or 1 μ g mL⁻¹ L2000) using the Quant-It PicoGreen assay and normalized to the value of pDNA alone.

^f Previously published peptide dendrimer as a co-transfection reagent with lipofectin displaying good pDNA transfection efficiency. ^g Viability and cytotoxicity assays were performed after 4 h of incubation of HEK cells with peptide dendrimers/pDNA complexes at N/P 5. Cytotoxicity was then determined using the Pierce LDH Cytotoxicity Assay Kit according to the manufacturer's instructions, and cell viability was assessed using the PrestoBlue reagent.






Fig. 2 Transfection efficiency on HEK spheroids. (a) Schematic representation of spheroid formation and evaluation of transfection. HEK cells were seeded in a 96-well ultra-low attachment U-bottom plate at 500 cells per well and after two days, spheroids were formed and transfected. 48 h after transfection, the spheroid size was ~250 µm. (b) Transfection efficiency of the best-performing compounds at N/P 5 (175 pmol of peptide dendrimers in 100 µL OptiMEM per well, 1.7 µM; 250 ng of pDNA per well in 100 µL OptiMEM, 0.42 nM), in the presence and in the absence of 10% FCS. The viability of HEK spheroids measured after 4 h of incubation with peptide dendrimers/pDNA best-performing complexes at N/P 5 and assessed by the PrestoBlue reagent. (c) Images of transfected spheroids. Transfected spheroids were imaged via both confocal and light (bright field) microscopies. Spheroids were fixed and stained with DAPI (blue), anti-GFP conjugated antibody (Alexa-Fluor488, green) and anti-collagen I conjugated antibody (Alexa-Fluor594, red). Images were taken using a Leica TCS SP8 confocal microscope with lens $\times 10$. Scale bar 50 µm. Acquisitions were taken with a step size of 2 µm between adjacent optical planes for 70 µm depth within the spheroid and Z-stack projects were made using ImageJ software.

L2000 in transfection efficiency. Finally, the exhaustive replacement of lysine residues with arginines in **Z20** provided **Z22**, which transfected up to 62.5% of HEK293 cells and 47.3% of HeLa cells with the CRISPR/Cas9 pDNA vector.

All dendrimers bound pDNA slightly better than L2000 or **G123KL**/lipofectin as measured using the picoGreen assay (Table 1).²⁸ However, there was no correlation between pDNA binding and transfection efficiency, which is not surprising considering that the percentage of GFP-positive cells reflects overall cellular uptake, intracellular pDNA release and protein expression.

The pDNA/dendrimer complexes did not reduce cell viability and were not cytotoxic in both cell lines (Table 1 and Table S2, ESI†). The best transfection dendrimer **Z22** was among the least problematic in the series, and only **Z1** showed significant toxicity but no reduction in cell viability. Additional testing showed that **Z20**, **Z21** and **Z22** preserved their excellent transfection efficiencies and low cytotoxicity at different N/P ratios, low concentration and in the presence of serum proteins, an important parameter for potential therapeutic applications (Fig. S1, ESI†). Furthermore, exposing THP-1 cells, which are

monocytes involved in innate immunity,²⁹ to the dendrimers alone or with pDNA did not induce any significant release of the pro-inflammatory cytokines Tumor necrosis factor α (TNF- α) or interleukin-1 β (IL-1 β) in comparison to the positive controls LPS³⁰ and PMA.³¹ We observed a moderate toxicity of the dendrimers on THP-1 cells; however, the toxic effect was entirely absent in the presence of 10% serum (Fig. S2, ESI†).

In view of their favourable transfection activities combined with low toxicity and low immunogenicity, we tested **Z20**, **Z21** and **Z22** for transfecting the CRISPR/Cas9 pDNA into 3D tumor spheroids from HEK cells and quantified transfection by FACS analysis upon spheroid destruction (Fig. 2a). All three peptide dendrimers had higher transfection efficiency than L2000, both in the presence and in the absence of serum proteins, while also preserving spheroid viability better than L2000 (Fig. 2b). Transfection was further evidenced by confocal imaging, which showed that cells throughout the spheroids were efficiently transfected (Fig. 2c and Fig. S3, ESI†).

To better understand pDNA transfection by our dendrimers, we further characterized **Z20**–**Z22**, as well as **Z1** and **Z12** as two less potent analogues. Dynamic light scattering showed that

dendrimer/pDNA complexes formed large nanoparticles ($\text{Rh} = 300 \text{ nm}$) at pH 7.4 similar to those formed between pDNA and the commercial reagents jetPEI or PEI (Fig. S4a, ESI[†]).^{32,33} These nanoparticles were only moderately stable as indicated by zeta potential values close to zero (Fig. S4b, ESI[†]), and by the fact that pDNA was readily displaced by heparin (Fig. S5, ESI[†]). The dendrimers formed aggregates even in the absence of pDNA at pH 7.4 at a critical micellar concentration (CMC $\sim 100 \mu\text{g mL}^{-1}$) corresponding to pDNA complexation as evidenced by the Nile Red assay.³⁴ However, the dendrimers were not aggregated at pH 5.0 corresponding to the acidified endosome (Fig. S6, ESI[†]), and had a different conformation at pH 7.4 and pH 5.0 as evidenced by circular dichroism spectra (Fig. S7, ESI[†]). These effects are probably triggered by the protonation of the eight amino termini, which occurs around pH 6.5 with such polycationic peptide dendrimers,^{21,35} leading to increased positive charge density and electrostatic repulsion between dendrimers.

These experiments suggest that **Z22** and its analogues mediate pDNA transfection through the same mechanism as dendrimers **DMH13** and **DMH18** for siRNA transfection,^{21,22} despite the very different sizes of their oligonucleotide cargo. This mechanism involves the aggregation and complexation of the oligonucleotide at pH 7.4 to form nanoparticles, which enter cells by endocytosis. Endosome acidification then induces protonation of the eight amino termini on the peptide dendrimer, resulting in partial disaggregation and endosome escape. Indeed, dendrimer mediated pDNA transfection was entirely blocked by inhibiting endosome acidification with baflomycin A1 (Fig. S8, ESI[†]).

In summary, we identified peptide dendrimer **Z22** as an exceptionally highly efficient reagent for transfecting large pDNA such as the CRISPR/Cas9 plasmid into cells and 3D-tumor spheroids, with low cytotoxicity and low immunogenicity. Similar to related peptide dendrimers,^{35–38} **Z22** is accessible in pure form by standard SPPS, which greatly facilitates its use.

This work was supported financially by the Marie Curie Training Network MMBIO (grant no. 721613) and the Swiss National Science Foundation (grants no. 200020_178998). We thank Dr Sacha Javor for his help in data interpretation and text editing.

Conflicts of interest

There are no conflicts to declare.

Notes and references

- 1 J. A. Doudna and E. Charpentier, *Science*, 2014, **346**, 1258096.
- 2 L. Cong, F. A. Ran, D. Cox, S. Lin, R. Barretto, N. Habib, P. D. Hsu, X. Wu, W. Jiang, L. A. Marraffini and F. Zhang, *Science*, 2013, **339**, 819–823.
- 3 L. Naldini, *Nature*, 2015, **526**, 351–360.
- 4 Z. Wu, H. Yang and P. Colosi, *Mol. Ther.*, 2010, **18**, 80–86.
- 5 G. Gernoux, A. M. Gruntman, M. Blackwood, M. Zieger, T. R. Flotte and C. Mueller, *Mol. Ther.*, 2020, **28**, 747–757.
- 6 H.-X. Wang, M. Li, C. M. Lee, S. Chakraborty, H.-W. Kim, G. Bao and K. W. Leong, *Chem. Rev.*, 2017, **117**, 9874–9906.
- 7 R. K. Jain and T. Stylianopoulos, *Nat. Rev. Clin. Oncol.*, 2010, **7**, 653–664.
- 8 L. Zhang, P. Hao, D. Yang, S. Feng, B. Peng, D. Appelhans, T. Zhang and X. Zan, *J. Mater. Chem. B*, 2019, **7**, 953–964.
- 9 G. Schwank, B.-K. Koo, V. Sasselli, J. F. Dekkers, I. Heo, T. Demircan, N. Sasaki, S. Boymans, E. Cuppen, C. K. van der Ent, E. E. S. Nieuwenhuis, J. M. Beekman and H. Clevers, *Cell Stem Cell*, 2013, **13**, 653–658.
- 10 M. Matano, S. Date, M. Shimokawa, A. Takano, M. Fujii, Y. Ohta, T. Watanabe, T. Kanai and T. Sato, *Nat. Med.*, 2015, **21**, 256–262.
- 11 M. Zanoni, F. Piccinini, C. Arienti, A. Zamagni, S. Santi, R. Polico, A. Bevilacqua and A. Tesei, *Sci. Rep.*, 2016, **6**, 19103.
- 12 M. Wojnilowicz, Q. A. Besford, Y.-L. Wu, X. J. Loh, J. A. Braunger, A. Glab, C. Cortez-Jugo, F. Caruso and F. Cavalieri, *Biomaterials*, 2018, **176**, 34–49.
- 13 N. S. Bhise, R. S. Gray, J. C. Sunshine, S. Htet, A. J. Ewald and J. J. Green, *Biomaterials*, 2010, **31**, 8088–8096.
- 14 R. Sapra, R. P. Verma, G. P. Maurya, S. Dhawan, J. Babu and V. Haridas, *Chem. Rev.*, 2019, **119**, 11391–11441.
- 15 C. C. Lee, J. A. MacKay, J. M. J. Frechet and F. C. Szoka, *Nat. Biotechnol.*, 2005, **23**, 1517–1526.
- 16 A.-M. Caminade, D. Yan and D. K. Smith, *Chem. Soc. Rev.*, 2015, **44**, 3870–3873.
- 17 Y. Dong, T. Yu, L. Ding, E. Laurini, Y. Huang, M. Zhang, Y. Weng, S. Lin, P. Chen, D. Marson, Y. Jiang, S. Giorgio, S. Prich, X. Liu, P. Rocchi and L. Peng, *J. Am. Chem. Soc.*, 2018, **140**, 16264–16274.
- 18 K. Ezzat, S. E. Andaloussi, E. M. Zaghoul, T. Lehto, S. Lindberg, P. M. Moreno, J. R. Viola, T. Magdy, R. Abdo, P. Guterstam, R. Sillard, S. M. Hammond, M. J. Wood, A. A. Arzumanov, M. J. Gait, C. I. Smith, M. Hallbrink and U. Langel, *Nucleic Acids Res.*, 2011, **39**, 5284–5298.
- 19 J. Hoyer and I. Neundorf, *Acc. Chem. Res.*, 2012, **45**, 1048–1056.
- 20 C. Douat, M. Bornerie, S. Antunes, G. Guichard and A. Kichler, *Bioconjugate Chem.*, 2019, **30**, 1133–1139.
- 21 M. Heitz, S. Javor, T. Darbre and J.-L. Reymond, *Bioconjugate Chem.*, 2019, **30**, 2165–2182.
- 22 M. Heitz, S. Zamolo, S. Javor and J.-L. Reymond, *Bioconjugate Chem.*, 2020, **31**, 1671–1684.
- 23 A. Kwok, G. A. Eggimann, J.-L. Reymond, T. Darbre and F. Hollfelder, *ACS Nano*, 2013, **7**, 4668–4682.
- 24 A. Kwok, G. A. Eggimann, M. Heitz, J. L. Reymond, F. Hollfelder and T. Darbre, *ChemBioChem*, 2016, **17**, 2223–2229.
- 25 M. Heitz, A. Kwok, G. A. Eggimann, F. Hollfelder, T. Darbre and J. L. Reymond, *Chimia*, 2017, **71**, 220–225.
- 26 O. Saher, C. S. J. Rocha, E. M. Zaghoul, O. P. B. Wiklander, S. Zamolo, M. Heitz, K. Ezzat, D. Gupta, J. L. Reymond, R. Zain, F. Hollfelder, T. Darbre, K. E. Lundin, S. El Andaloussi and C. I. E. Smith, *Eur. J. Pharm. Biopharm.*, 2018, **132**, 29–40.
- 27 A. L. Szymczak, C. J. Workman, Y. Wang, K. M. Vignali, S. Dilioglou, E. F. Vanin and D. A. A. Vignali, *Nat. Biotechnol.*, 2004, **22**, 589–594.
- 28 S. J. Ahn, J. Costa and J. R. Emanuel, *Nucleic Acids Res.*, 1996, **24**, 2623–2625.
- 29 O. Takeuchi and S. Akira, *Cell*, 2010, **140**, 805–820.
- 30 S. Mariathasan, D. S. Weiss, K. Newton, J. McBride, K. O'Rourke, M. Roose-Girma, W. P. Lee, Y. Weinrauch, D. M. Monack and V. M. Dixit, *Nature*, 2006, **440**, 228–232.
- 31 E. Kontny, M. Ziolkowska, A. Ryżewska and W. Maśliński, *Cytokine*, 1999, **11**, 839–848.
- 32 X. Chen, Z. Yuan, X. Yi, R. Zhuo and F. Li, *Nanotechnology*, 2012, **23**, 415602.
- 33 Z. Tan, Y. Jiang, W. Zhang, L. Karls, T. P. Lodge and T. M. Reineke, *J. Am. Chem. Soc.*, 2019, **141**, 15804–15817.
- 34 M. C. A. Stuart, J. C. van de Pas and J. B. F. N. Engberts, *J. Phys. Org. Chem.*, 2005, **18**, 929–934.
- 35 B.-H. Gan, T. N. Siriwardena, S. Javor, T. Darbre and J.-L. Reymond, *ACS Infect. Dis.*, 2019, **5**, 2164–2173.
- 36 J.-L. Reymond and T. Darbre, *Org. Biomol. Chem.*, 2012, **10**, 1483–1492.
- 37 T. N. Siriwardena, M. Stach, R. He, B.-H. Gan, S. Javor, M. Heitz, L. Ma, X. Cai, P. Chen, D. Wei, H. Li, J. Ma, T. Köhler, C. van Delden, T. Darbre and J.-L. Reymond, *J. Am. Chem. Soc.*, 2018, **140**, 423–432.
- 38 T. N. Siriwardena, A. Capecci, B. H. Gan, X. Jin, R. He, D. Wei, L. Ma, T. Kohler, C. van Delden, S. Javor and J. L. Reymond, *Angew. Chem. Int. Ed.*, 2018, **57**, 8483–8487.

